BiotechTube

Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue Medications

Phase 1/2Recruiting
2 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Small Cell Lung Cancer Extensive Stage

Conditions

Small Cell Lung Cancer Extensive Stage

Trial Timeline

Jan 29, 2026 → Dec 30, 2030

NCT ID
NCT07227597

About Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue Medications

Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue Medications is a phase 1/2 stage product being developed by Daiichi Sankyo for Small Cell Lung Cancer Extensive Stage. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07227597. Target conditions include Small Cell Lung Cancer Extensive Stage.

What happened to similar drugs?

20 of 20 similar drugs in Small Cell Lung Cancer Extensive Stage were approved

Approved (20) Terminated (2) Active (0)
✅mouse nerve growth factorSun PharmaceuticalApproved
✅Pemetrexed + CarboplatinEli LillyApproved
✅pemetrexedEli LillyApproved
✅Osimertinib+cisplatin or carboplatin + pemetrexed EditAstraZenecaApproved
✅DurvalumabAstraZenecaApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅OsimertinibAstraZenecaApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07227597Phase 1/2Recruiting

Competing Products

20 competing products in Small Cell Lung Cancer Extensive Stage

See all competitors
ProductCompanyStageHype Score
mRNA-1769ModernaPhase 2
0
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
LY3295668 ErbumineEli LillyPhase 1
29
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37
pemetrexed + cisplatinEli LillyPhase 2
27
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
pemetrexed + docetaxelEli LillyPhase 3
40
enzastaurin + pemetrexed + docetaxel + carboplatinEli LillyPhase 2
35
PemCarbo + Pem onlyEli LillyPhase 3
36
TNG456 + abemaciclibEli LillyPhase 1/2
39